Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib + fulvestrant versus maintenance chemotherapy in PIK3CA-mutated advanced breast cancer (SAFIR-PI3K / SAFIR02 Breast pooled analysis)
2017-000154-19Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of alpelisib in breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival. Started Jul 2017; status: completed.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-000154-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000154-19.